Fig. 5From: Respiratory syncytial virus prophylaxis for prevention of recurrent childhood wheeze and asthma: a systematic reviewSub-group analysis among pre-term infants with gestational age 32 to < 36 weeks. This sub-group analysis demonstrates a relative risk of 0.35 (95% CI = 0.14–0.86), showing a statistically significant reduction in risk of recurrent wheeze among this cohort of preterm infants with palivizumab useBack to article page